A survey of 164 US adults published last week in npj Digital Medicine suggests that while many individuals seeking psychotherapy for depression would consider a digital treatment with or without supplementary support, a one-on-one in-person visit is still the most popular option due to concerns of efficacy, access and confidentiality.
Topline data
Forty-nine percent of the survey’s eligible...
A newly announced study backed by Takeda Pharmaceuticals, Lundbeck US, and Advocate Health Care will explore the effectiveness of a mobile app designed to improve engagement between patients with major depressive disorder (MDD) and their providers.
The investigation will use the Advocate Pathway App to capture the start of or any adjustments to a patient’s antidepressant therapy. Through a...
Smartphone apps designed for those with depression can significantly reduce users’ symptoms, according to the results of a recently published meta-analysis. While the findings are limited to those with mild-to-moderate depression, the apps’ consistent effect across age and gender suggest that the benefits are wide reaching.
"The majority of people in developed countries own smartphones, including...
Like many cognitive illnesses, clinical depression isn’t a steady state but a variable condition that has patterns and symptoms that change over time and throughout daily life. So Takeda Pharmaceuticals and Cognition Kit are collaborating on a study to assess whether mobile apps and wearables with continuous monitoring capabilities can be used to glean new insights into major depressive disorder...
By Neil Versel
It’s time for a reality check in mobile and wireless home health, specifically in the area of body sensors. And this bit of buzzkill comes from someone at the forefront of the field, namely Dr. Joseph Kvedar, director of the Center for Connected Health at Partners HealthCare System in Boston.
“Most of the time, I write from the perspective of a technology vision that includes...
